98%
921
2 minutes
20
Purpose Of Review: The rising prevalence of atherosclerosis has prompted the development of novel diagnostic methods capable of identifying early-stage disease when therapeutic interventions may be most effective. F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) is a molecular imaging technique that can quantify subclinical microcalcification in arterial plaque. The focus of this review article is to discuss the utility of F-NaF PET/CT in assessing atherosclerotic disease of major susceptible blood vessels, particularly the coronary arteries and thoracic aorta.
Recent Findings: F-NaF uptake observed on PET imaging demonstrates promising potential as a marker of atherosclerotic burden in individual coronary arteries, whole heart segmentations, and the thoracic aorta. Global versus focal assessment of F-NaF uptake in small arteries is a significant source of methodological heterogeneity among studies. The accuracy and reproducibility of F-NaF PET/CT may be improved by standardized quantification methods in light of the limited spatial resolution of PET, particularly through the use of techniques to evaluate global atherosclerotic burden.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078425 | PMC |
http://dx.doi.org/10.1007/s11886-025-02240-9 | DOI Listing |
Connect Tissue Res
August 2025
Department of Orthopaedic Surgery, Washington University in St. Louis, MO, USA.
Osteoarthritis (OA) is a complex, multifactorial joint disease and a leading contributor to global disability. Despite its high prevalence and socioeconomic burden, no curative or preventive therapies currently exist. The ability to detect early OA, or even "pre-OA" could provide the opportunity for earlier interventions.
View Article and Find Full Text PDFAm Heart J
December 2025
Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address:
Background: Aortic valve stenosis (AS) is one of the most common valvular heart diseases worldwide. Its prevalence increases with age and is expected to rise further as the population ages. Untreated severe AS carries a 2-year mortality rate exceeding 50%.
View Article and Find Full Text PDFHeart Fail Clin
July 2025
Department of Interventional Cardiology and Angiology, KKiAI, Institute of Cardiology, Alpejska 42, Warsaw 04-628, Poland. Electronic address:
PET allows the assessment of cardiovascular pathophysiology across a wide range of cardiovascular conditions. By imaging processes directly involved in disease progression and adverse events, such as inflammation and developing calcifications (microcalcifications), PET can not only enhance our understanding of cardiovascular disease, but also, as shown for 18F-sodium fluoride, has the potential to predict hard endpoints. In this review, the recent advances in disease activity assessment with cardiovascular PET, which provide hope that this promising technology could be leveraged in the clinical setting, shall be discussed.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
June 2025
Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Jansen's metaphyseal chondrodysplasia (JMC) is a rare disorder caused by activating mutations in the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor (PTH1R). Patients exhibit short stature, dysmorphic bones, and severe growth plate abnormalities, as well as hypercalcemia, hypercalciuria, hypophosphatemia, and reduced plasma PTH levels. Humanized PTH1R (hPTH1R) mice expressing the H223R-hPTH1R JMC mutation die early without breeding.
View Article and Find Full Text PDFJACC Cardiovasc Imaging
July 2025
Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Positron emission tomography (PET)/computed tomography is a major imaging strategy for cardiovascular disease characterization. Whereas multiple radioisotopes can be used for PET imaging of cardiac disease processes, fluorine-18 (F) presents key advantages. These include availability as a unit dose given a favorable half-life of 109.
View Article and Find Full Text PDF